Where does Glaxosmithkline Biologicals SA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Glaxosmithkline Biologicals SA ranks #1,007 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Glaxosmithkline Biologicals SA hold?

Glaxosmithkline Biologicals SA holds 436 US utility patents granted between 2015 and 2025, spanning 31 technology areas.

What is Glaxosmithkline Biologicals SA's Innovation Score?

Glaxosmithkline Biologicals SA has an Innovation Score of 58.3 out of 100 (top 5% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Glaxosmithkline Biologicals SA's patent grant rate increasing or decreasing?

Glaxosmithkline Biologicals SA's recent grant velocity is -16% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Glaxosmithkline Biologicals SA's patents?

Glaxosmithkline Biologicals SA's patents average 17.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Glaxosmithkline Biologicals SA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Glaxosmithkline Biologicals SA

Q: What technology areas does Glaxosmithkline Biologicals SA focus on?

Glaxosmithkline Biologicals SA's top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 409 patents. Grants appear in 31 CPC subclasses total.

USPTO PatentsView assignee record - 436 granted patents across 31 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Glaxosmithkline ranks #1,007 of 49,997 tracked US assignees by granted-patent volume, with 436 patents across 31 technology areas.

#1,007
of 49,997 US assignees by volume: Top 5%
by Innovation Score (58.3/100): 17.7
avg claims per patent: -16%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1007 · Foreign Corporation #1,007 · 436 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 436 grants
TOP-DECILE #1,007/49,997
PHOTO-FINISH Advantest
CPC-FOCUS A61K · 31 areas
INNOV-PAR 58.3/100
CLAIMS-RICH 17.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -16% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Advantest Corporation (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Glaxosmithkline… · this assignee

58
I-sens · near

58
Perkins Engines · near

58
Sartorius Stedim… · near

58
V-nova International · near

58
3D Lighting… · lowest

7

What this shows Glaxosmithkline's Innovation Score is 58.3/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Glaxosmithkline's grants concentrate

Glaxosmithkline Biologicals SA is a focused PatentsView assignee: 31 CPC subclasses with 93.8% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2016 (57 grants) versus a trough of 32 in 2021. By volume, Glaxosmithkline sits between Nuvoton Technology Corporation and National Chiao Tung University.

Glaxosmithkline's three-year grant acceleration

From 2019–2021 to 2022–2024, Glaxosmithkline Biologicals SA moved from 117 to 123 grants (1.05x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,060. See the growth leaderboard.

Nuvoton Technology

438
Advantest

437
Block

437
Harris

437
Glaxosmithkline B… ◀

436
Ferrari S p A

435
Hansgrohe SE

435
Akamai

434
National Chiao Tu…

434

What this shows Glaxosmithkline holds 436 patents at rank #1,007, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Glaxosmithkline

By rank, the assignees closest to #1,007 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Glaxosmithkline's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Glaxosmithkline, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (58 here).

Sartorius Stedim Biotech GmbH 58 V-nova International Limited 58 Perkins Engines Company Limited 58 I-sens, Inc. 58

Similar claim depth

Nearest assignees by average claims per patent (17.7 here).

KHS GmbH 17.7 avg Spine Wave, Inc. 17.7 avg Edwards Lifesciences CardiAQ LLC 17.7 avg Tornier 17.7 avg

Glaxosmithkline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Glaxosmithkline Biologicals SA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	35	8.0%
2016	57	13.1%
2017	54	12.4%
2018	37	8.5%
2019	47	10.8%
2020	38	8.7%
2021	32	7.3%
2022	34	7.8%
2023	52	11.9%
2024	37	8.5%
2025partial year	13	3.0%

Which technologies does Glaxosmithkline Biologicals SA patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 409

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 341

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 212

C07K - Peptides 200

Y02A - Technologies FOR Adaptation TO Climate Change 180

C08B - POLYSACCHARIDES; Derivatives Thereof 23

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 23

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 22

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 18

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 15

C12Y - Enzymes 15

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 7

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 6

B01D - Separation 6

C07D - Heterocyclic Compounds 6

Top 15 of 31 technology areas

Where it ranks

Overall rank by patents

#1,007

of 49,997 tracked assignees

Innovation Score

58.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Glaxosmithkline Biologicals SA's patent record in context - here's where to go next.

Glaxosmithkline Biologicals SA's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 93.8% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #1,007 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Glaxosmithkline Biologicals SA against Nuvoton Technology Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 58.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.